Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
A phase 2 trial of Apalutamide in prostate cancer, run by Monte Rosa Therapeutics, Inc, now recruiting.
Overview
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer is a phase 2 interventional study registered as NCT07745361 by Monte Rosa Therapeutics, Inc, with 25 participants planned, started 2026-08 and due to reach its primary completion in 2027-10. Interventions recorded: Oral MRT-2359, Apalutamide. Conditions listed: Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Apalutamide, Prostate cancer.
- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Apalutamide, Prostate cancer.
- TrialA Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Shares Apalutamide, Prostate cancer.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Apalutamide, Prostate cancer.
- TrialA Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Shares Apalutamide, Prostate cancer.
- TrialStudy of Oral MRT-2359 in Selected Cancer Patients
Shares Monte Rosa Therapeutics, Prostate cancer.
- TrialAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Shares Apalutamide, Prostate cancer.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Apalutamide, Prostate cancer.